Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals for the treatment of ulcerative colitis and Crohn's disease under the trade name Entyvio. Vedolizumab binds to integrin _4_7 (LPAM-1) and blocks _4_7, displaying anti-inflammatory activity.